The association between immunosuppressant and the outcome of COVID-19

We read with great interest the study investigating the association between immunosuppressant and the outcome of patients withs SARS-CoV-2 infection [1]. They found that the prior use of immunosuppressant would be associated with a significantly increased risk of death (adjusted relative risk [RR],...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Chi-Kuei, Lai, Chih-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248176/
https://www.ncbi.nlm.nih.gov/pubmed/35777768
http://dx.doi.org/10.1183/13993003.00816-2022
_version_ 1784739315640696832
author Hsu, Chi-Kuei
Lai, Chih-Cheng
author_facet Hsu, Chi-Kuei
Lai, Chih-Cheng
author_sort Hsu, Chi-Kuei
collection PubMed
description We read with great interest the study investigating the association between immunosuppressant and the outcome of patients withs SARS-CoV-2 infection [1]. They found that the prior use of immunosuppressant would be associated with a significantly increased risk of death (adjusted relative risk [RR], 1.56; 95% CI, 1.10–2.22) which was mainly driven by exposure to systemic glucocorticoids (aRR, 2.38; 95% CI 1.72–3.30). Overall, it is a well-designed study; however, we have three concerns about the findings of this study.
format Online
Article
Text
id pubmed-9248176
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-92481762022-07-05 The association between immunosuppressant and the outcome of COVID-19 Hsu, Chi-Kuei Lai, Chih-Cheng Eur Respir J Correspondence We read with great interest the study investigating the association between immunosuppressant and the outcome of patients withs SARS-CoV-2 infection [1]. They found that the prior use of immunosuppressant would be associated with a significantly increased risk of death (adjusted relative risk [RR], 1.56; 95% CI, 1.10–2.22) which was mainly driven by exposure to systemic glucocorticoids (aRR, 2.38; 95% CI 1.72–3.30). Overall, it is a well-designed study; however, we have three concerns about the findings of this study. European Respiratory Society 2022-07-01 /pmc/articles/PMC9248176/ /pubmed/35777768 http://dx.doi.org/10.1183/13993003.00816-2022 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Correspondence
Hsu, Chi-Kuei
Lai, Chih-Cheng
The association between immunosuppressant and the outcome of COVID-19
title The association between immunosuppressant and the outcome of COVID-19
title_full The association between immunosuppressant and the outcome of COVID-19
title_fullStr The association between immunosuppressant and the outcome of COVID-19
title_full_unstemmed The association between immunosuppressant and the outcome of COVID-19
title_short The association between immunosuppressant and the outcome of COVID-19
title_sort association between immunosuppressant and the outcome of covid-19
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248176/
https://www.ncbi.nlm.nih.gov/pubmed/35777768
http://dx.doi.org/10.1183/13993003.00816-2022
work_keys_str_mv AT hsuchikuei theassociationbetweenimmunosuppressantandtheoutcomeofcovid19
AT laichihcheng theassociationbetweenimmunosuppressantandtheoutcomeofcovid19
AT hsuchikuei associationbetweenimmunosuppressantandtheoutcomeofcovid19
AT laichihcheng associationbetweenimmunosuppressantandtheoutcomeofcovid19

Ejemplares similares